A new study indicates that COVID-19 is associated with an elevated risk of a rare disorder, Guillain-Barré syndrome, within six weeks after infection with the virus.

Sept. 24 (UPI) --People with COVID-19 may be at increased risk for developing Guillain-Barre syndrome, a study published Friday by the journal Brain found. Eleven of 49 patients with the rare ...

The researcher, María Dolores Calabria Gallego, carried out a bibliographic review investigating Guillain-Barre disease and COVID-19. Four hundred five initial results were rapidly sorted, ...

Reference: Nasreen S, Jiang Y, Lu H, et al. Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study. Vaccine.

A new paper in Brain, published by Oxford University Press, indicates that a COVID-19 infection may prompt Guillain-Barré syndrome. Since early 2020, the COVID-19 pandemic has affected the entire ...

Having a COVID-19 infection is associated with an increased risk of developing the rare disorder called Guillain-Barré syndrome within the next six weeks, according to a study published in the ...

Two studies published in Annals of Neurology reported small clusters “of an unusual variant of Guillain-Barre syndrome” following receipt of a COVID-19 vaccine, according to a press release ...

Johnson & Johnson’s beleaguered Covid-19 vaccine may be associated with a small increased risk of Guillain–Barré syndrome, a rare but potentially serious neurological condition, federal ...

FDA. Fact sheet for recipients and caregivers emergency use authorization (EUA) of the Janssen covid-19 vaccine to prevent coronavirus disease 2019 (COVID-19) in individuals 18 years of age and older.

New research links the rare neurological condition Guillain-Barré syndrome to covid-19. The study tracked millions of people in Israel, finding that those with a recent history of covid-19 ...

Some people who got the Johnson & Johnson/Janssen COVID-19 vaccine (the one-dose vaccine) have developed a condition known as Guillain-Barré syndrome. It’s happened often enough that the FDA ...